276 related articles for article (PubMed ID: 18565735)
1. Autoantibodies against matrix metalloproteinase-1 in patients with localized scleroderma.
Tomimura S; Ogawa F; Iwata Y; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
J Dermatol Sci; 2008 Oct; 52(1):47-54. PubMed ID: 18565735
[TBL] [Abstract][Full Text] [Related]
2. Decreased levels of autoantibody against histone deacetylase 3 in patients with systemic sclerosis.
Kuwatsuka Y; Ogawa F; Iwata Y; Komura K; Muroi E; Hara T; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
Autoimmunity; 2009 Feb; 42(2):120-5. PubMed ID: 19021012
[TBL] [Abstract][Full Text] [Related]
3. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma.
Hayakawa I; Hasegawa M; Takehara K; Sato S
Arthritis Rheum; 2004 Jan; 50(1):227-32. PubMed ID: 14730620
[TBL] [Abstract][Full Text] [Related]
4. Anti-DNA topoisomerase II alpha autoantibodies in Japanese patients with systemic sclerosis.
Hayakawa I; Hasegawa M; Takehara K; Sato S
Arch Dermatol Res; 2005 Oct; 297(4):180-3. PubMed ID: 16180014
[TBL] [Abstract][Full Text] [Related]
5. Antinucleosome antibody is a major autoantibody in localized scleroderma.
Sato S; Kodera M; Hasegawa M; Fujimoto M; Takehara K
Br J Dermatol; 2004 Dec; 151(6):1182-8. PubMed ID: 15606513
[TBL] [Abstract][Full Text] [Related]
6. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis.
Nishijima C; Hayakawa I; Matsushita T; Komura K; Hasegawa M; Takehara K; Sato S
Clin Exp Immunol; 2004 Nov; 138(2):357-63. PubMed ID: 15498049
[TBL] [Abstract][Full Text] [Related]
7. Anti-phosphatidylserine-prothrombin complex antibodies in patients with localized scleroderma.
Hasegawa M; Fujimoto M; Hayakawa I; Matsushita T; Nishijima C; Yamazaki M; Takehara K; Sato S
Clin Exp Rheumatol; 2006; 24(1):19-24. PubMed ID: 16539814
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies against calpastatin in sera from patients with systemic sclerosis.
Sato S; Hasegawa M; Nagaoka T; Takamatsu Y; Yazawa N; Ihn H; Kikuchi K; Takehara K
J Rheumatol; 1998 Nov; 25(11):2135-9. PubMed ID: 9818655
[TBL] [Abstract][Full Text] [Related]
9. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis.
Hara T; Ogawa F; Muroi E; Komura K; Takenaka M; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2008 Mar; 35(3):451-7. PubMed ID: 18203319
[TBL] [Abstract][Full Text] [Related]
10. Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress.
Iwata Y; Ogawa F; Komura K; Muroi E; Hara T; Shimizu K; Hasegawa M; Fujimoto M; Tomita Y; Sato S
Rheumatology (Oxford); 2007 May; 46(5):790-5. PubMed ID: 17309887
[TBL] [Abstract][Full Text] [Related]
11. Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations.
Kodera M; Hayakawa I; Komura K; Yanaba K; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2005 Apr; 32(4):629-36. PubMed ID: 15801017
[TBL] [Abstract][Full Text] [Related]
12. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E
Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902
[TBL] [Abstract][Full Text] [Related]
13. Antigen specificity of antihistone antibodies in localized scleroderma.
Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
Arch Dermatol; 1994 Oct; 130(10):1273-7. PubMed ID: 7524451
[TBL] [Abstract][Full Text] [Related]
14. Anti-fibroblast antibodies detected by cell-based ELISA in systemic sclerosis enhance the collagenolytic activity and matrix metalloproteinase-1 production in dermal fibroblasts.
Fineschi S; Cozzi F; Burger D; Dayer JM; Meroni PL; Chizzolini C
Rheumatology (Oxford); 2007 Dec; 46(12):1779-85. PubMed ID: 17982166
[TBL] [Abstract][Full Text] [Related]
15. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis.
Sato S; Hayakawa I; Hasegawa M; Fujimoto M; Takehara K
J Invest Dermatol; 2003 Apr; 120(4):542-7. PubMed ID: 12648215
[TBL] [Abstract][Full Text] [Related]
16. Anti-agalactosyl immunoglobulin G antibodies in localized scleroderma.
Mimra Y; Ihn H; Jinnin M; Asano Y; Yamane K; Yazawa N; Tamaki K
Int J Dermatol; 2005 Oct; 44(10):817-20. PubMed ID: 16207181
[TBL] [Abstract][Full Text] [Related]
17. Autoantibodies against phosphatidylserine-prothrombin complex in patients with systemic sclerosis.
Hasegawa M; Sato S; Yanaba K; Komura K; Yamazaki M; Takehara K
Ann Rheum Dis; 2004 Nov; 63(11):1514-7. PubMed ID: 15479907
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and characteristics of anti-single-stranded DNA antibodies in localized scleroderma. Comparison with systemic lupus erythematosus.
Ruffatti A; Peserico A; Rondinone R; Calligaro A; Del Ross T; Ghirardello A; Germino M; Todesco S
Arch Dermatol; 1991 Aug; 127(8):1180-3. PubMed ID: 1863075
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma.
Nagaoka T; Sato S; Hasegawa M; Ihn H; Takehara K
J Rheumatol; 2000 Aug; 27(8):1917-21. PubMed ID: 10955333
[TBL] [Abstract][Full Text] [Related]
20. Novel autoantibody to Cu/Zn superoxide dismutase in patients with localized scleroderma.
Nagai M; Hasegawa M; Takehara K; Sato S
J Invest Dermatol; 2004 Mar; 122(3):594-601. PubMed ID: 15086540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
